Navigation Links
DURECT Reports Data From European Phase IIb Hysterectomy Study of POSIDUR(TM) (SABER(TM)-Bupivacaine)
Date:6/16/2010

ebo (with all groups taking the background and supplemental pain treatment as described above) in terms of pain intensity on movement area under the curve (AUC) during the period 1-72 hours post-surgery, and (2) superiority of POSIDUR against SABER-Placebo in the total use of opioid rescue analgesia 0-72 hours post-surgery.  Results from this study show that the first primary endpoint was met.  With respect to the second primary efficacy endpoint, no statistically significant difference was shown in opioid use between the POSIDUR and SABER-Placebo groups.  Secondary comparisons were performed towards the active comparator group with similar results.  In this study, patients in all treatment groups only took a meaningful amount of opioids during a shorter period of time after surgery than was expected.

In this study, there were no indications of systemic safety issues.  The plasma concentration profiles were consistent with previous studies, confirming the sustained release profile of the product.  Local observations (most commonly coded as post procedural haematomas) at the surgical site were observed with frequency in the POSIDUR and SABER-Placebo groups and not observed in the active comparator group.  These events were temporary and resolved without treatment.

"The data from this study further supports the CNS and cardiovascular safety profile of POSIDUR in another surgical model, but when few opioids are taken, it is difficult to show a reduction in opioid use," stated James E. Brown, President and CEO of DURECT Corporation.  "We are currently enrolling in BESST, our U.S. pivotal Phase III study and Nycomed continues to enroll in a Phase IIb study in Europe in shoulder surgery.  In addition, we had a recent FDA interaction which increased our confidence that the BESST design and overall NDA s
'/>"/>

SOURCE DURECT Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. DURECT Announces Positive ELADUR(TM) Phase IIa Study Results
2. ELADUR(TM) Development Update: DURECT Receives Orphan Drug Designation for Bupivacaine for Post-Herpetic Neuralgia
3. DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program
4. DURECT Corporation Invites You to Join its Third Quarter 2009 Earnings Conference Call
5. DURECT to Present at the 21st Annual Piper Jaffray Health Care Conference
6. DURECT Corporation Invites You to Join Its Fourth Quarter 2009 Earnings Conference Call
7. DURECT and Nycomed Amend POSIDUR(TM) License Agreement to Separate Funding and Control of U.S. and E.U. Clinical Programs and to Expand Territory
8. DURECT Corporation Announces Fourth Quarter and Year End 2009 Financial Results
9. DURECT to Present at the Cowen and Company Healthcare Conference
10. DURECT to Present at the Barclays Capital Global Healthcare Conference
11. DURECT Corporation Invites You to Join Its First Quarter 2010 Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015  Organovo Holdings, ... company focused on delivering breakthrough 3D bioprinting technology, ... and Chief Executive Officer, will present live at ... invite you to join us for this Company ... updates on our commercial launch of the exVive3D ...
(Date:2/27/2015)... , Feb. 27, 2015  Uroplasty, Inc. (NASDAQ: ... manufactures and markets innovative proprietary products to treat voiding ... 27th Annual ROTH Conference on Tuesday, March 10, 2015. ... Brett Reynolds , Chief Financial Officer, will present at ... on one at the conference at the Ritz Carlton ...
(Date:2/27/2015)... JERUSALEM , Feb. 27, 2015  Chiasma, Inc., ... lead product for the orphan condition acromegaly, today announced ... round. Participants in the financing included new investors Rock ... chip public investment fund, as well as existing investors ... and ARCH Venture Partners. Chiasma intends ...
Breaking Medicine Technology:Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 2Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 4Uroplasty to Participate in the 27th Annual ROTH Conference 2Chiasma Announces Completion of $70 Million Series E Financing 2Chiasma Announces Completion of $70 Million Series E Financing 3
... ,SARAH, - a French national collaborative randomized controlled ... sorafenib in advanced hepatocellular carcinoma is now open ... a new randomized controlled trial to directly compare ... (SIR-Spheres ® microspheres; Sirtex Medical Limited, Australia) ...
... 2, 2012  On February 2, at the Late-Breaking Science Session ... the TREVO Study ( T hrombectomy ... O cclusions in acute ischemic stroke). This ... clot-removing stent retriever technology. Sixty patients were enrolled by seven ...
Cached Medicine Technology:New Study of Primary Liver Cancer Seeks to Enroll 400 French Patients 2New Study of Primary Liver Cancer Seeks to Enroll 400 French Patients 3New Study of Primary Liver Cancer Seeks to Enroll 400 French Patients 4Stryker Presents Results of the TREVO Prospective Clinical Study at the International Stroke Conference 2
(Date:3/1/2015)... 2015 ERISAPros is pleased ... Roddy to the professional staff of its Compliance Department. ... The Ohio State University-Mortiz College of Law. Prior to ... working with several Fortune 500 companies as well as ... corporate benefits. Her experiences range from benefit plan design, ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 In recent years ... number of practicing physicians as a way for them to ... education regarding Cannabis as medicine. Since the FDA still lists ... few resources available to licensed physicians that can help ... patient. Dr. Deborah Malka in Santa Cruz, CA is ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 The Heart ... now a distributor of the machine. The Heart Fit ... their license, like a franchise model. The goal is ... and reverse heart disease. To buy External Counterpulsation ... Clinic can help individuals through this process and achieve ...
(Date:2/28/2015)... Indosoft Inc , developers of ... are pleased to announce the development of Q-Suite 5.9. ... versions of Q-Suite, this new version will include enhancements ... new features to the leading edge call center software. ... will add features to enhance security and protection. Administrators ...
(Date:2/28/2015)... 2015 National Sales Solutions ... marketing and supply chain management for consumer packaged ... bringing its award winning solutions for thinning-damaged hair ... are specifically created to combat thinning-damaged hair. ... committed to marrying science with nature to create ...
Breaking Medicine News(10 mins):Health News:ERISAPros Recruits Evelyn King, J.D. and Carolyn Roddy, J.D. to its Professional Staff 2Health News:Reputable Cannabis Doctor In Santa Cruz and Monterey Joins the Medical Cannabis Network 2Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Indosoft Proudly Announces Q-Suite 5.9 Call Center Software for Asterisk 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3
... from the United States and Saudi Arabia are working to ... The therapy has been shown to restore lost vision ... is being funded in part by a $1.5 million grant ... Arabia, where the recessive gene mutation that leads to the ...
... , , , ... the historic port of Southampton, England, before an audience of press, travel ... Equinox - was officially named. , , ... by a piano rendition of the Beatles, classic "Here Comes the Sun," ...
... , , , , ... Circulation Research : Journal of the American Heart Association. , ... the Institute of Molecular Cardiology at the University of Louisville in Kentucky, will assume ... 30. , , "It is an honor and a privilege to ...
... , DALLAS, July 29 Unified360, a ... Surgical Hospital at Fort Worth. Unified360 was selected because of ... critical large scale implementations. , , "Healthcare is ... of Unified360. "We are seeing a lot of activity in this ...
... , , PASSAIC, N.J., July 29 ... 8 other House Representatives have introduced the "DON,T LET THE BED ... states efforts to root out the ever increasing Bed Bug problem that ... Consumer Products has released the first and only non-toxic Bed ...
... ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), today announced it ... 5, 2009. In conjunction, the Company will host a conference call at ... update. , , Date: ... Conference call access:, Internet: www.istavision.com, ...
Cached Medicine News:Health News:Developing gene therapy to fight blindness 2Health News:'Here Comes the Sun': Celebrity Equinox Named in Southampton 2Health News:'Here Comes the Sun': Celebrity Equinox Named in Southampton 3Health News:Bolli Becomes New Editor-In-Chief of Circulation Research 2Health News:Bolli Becomes New Editor-In-Chief of Circulation Research 3Health News:Bolli Becomes New Editor-In-Chief of Circulation Research 4Health News:Unified360 Makes Positive Impact to Baylor Surgical Center Operations. 2Health News:U.S. Congress Introduces H.R. 2248 'DON'T LET THE BED BUGS BITE ACT OF 2009' 2
... the user to quickly and accurately count bacteria ... counting or manual counting. An optional 1.5X auxiliary ... to 3.0X. The adjustable focusing rod allows the ... The lens also rotates a full 360 for ...
The Accucount 2000 is designed to automatically count microscopic objects in a field displaying totals on a highly visible digital readout....
... Petri dish in 3 seconds. The counts ... the colonies as compared to those of ... three types of lighting: lower lighting for ... the agar and upper lighting for blood ...
Basic critical care testing. Measures pH, pCO2, and pO2 from 85 L whole-blood sample....
Medicine Products: